CKD anemia market to hit $5.3B by 2034, fueled by HIF-PH inhibitor innovation, despite rising generic competition and persistent unmet patient needs.

An expert discusses how a 67-year-old woman with symptomatic anemia was diagnosed with lower-risk MDS and treated with luspatercept as first-line therapy.

Anemia, a critical and debilitating complication of CKD, accelerates disease progression and exacerbates its overall burden. Despite numerous studies exploring the prevalence and determinants of ...

Acquired aplastic anemia is a rare, life-threatening hematological disorder characterized by bone marrow failure resulting in pancytopenia, or the reduction of red blood cells, white blood cells, and ...